New Project Puts Standardized Outcomes Measures for Depression into Real-World Use, from Registries to the Clinic

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOSTON, July 22, 2019 /PRNewswire/ — OM1, a leading health outcomes and technology company, today announced it is has been awarded the CAPSTONE – Outcome Measure Harmonization and Data Infrastructure for Patient Centered Outcomes Research in Depression project by the U.S. Agency for Healthcare Research and Quality (AHRQ).  Under this contract, OM1 and its provider partners, the American Board of Family Medicine (ABFM), the American Psychiatric Association (APA), and health systems, will work to implement standardized outcomes measures for depression in research and clinical settings for better informed decision making.

OM1 (PRNewsfoto/OM1)OM1 (PRNewsfoto/OM1)

The project will implement standardized outcomes measures for depression in two patient registries (the ABFM’s PRIME Registry and the APA’s PsychPRO registry) and in health systems.

The project will demonstrate the ability to collect standardized outcomes from electronic health record (EHR) and patient reported outcome (PRO) systems, exchange information with registries, and feed back measurement to clinicians through a standards-based application in their usual workflow.  

This project is funded by the Office of the Secretary’s Patient-Centered Outcomes Research Trust Fund (OS-PCORTF)* and builds on prior AHRQ-funded efforts to develop and use the Outcome Measures Framework (OMF) to create harmonized libraries of outcome measures in five condition areas, including depression.  

“Measuring and reporting outcomes in a standard way is critical to being able to fully understand and compare treatment effectiveness, benefit and risk and to enable better collaboration across stakeholders,” said Dr. Rich Gliklich, founder and CEO, OM1. “This initiative is an important step toward improving patient outcomes and delivering more personalized treatments in depression.”

*This work is supported by the Office of the Secretary Patient-Centered Outcomes Research Trust Fund under Interagency Agreement 18-596R-18 through Agency for Healthcare Research and Quality contract no. 75Q80119C00005.

Contact
Renee Hurley, OM1
(617) 620-9571
Rhurley@om1.com

About OM1
OM1 is a health outcomes and technology company leveraging big clinical data and AI to better understand, compare, and predict patient outcomes. OM1’s real world evidence platform, clinical registries and AI technologies enable clients to accelerate research, measure and benchmark health outcomes and to personalize patient care.

View original content to download multimedia:http://www.prnewswire.com/news-releases/new-project-puts-standardized-outcomes-measures-for-depression-into-real-world-use-from-registries-to-the-clinic-300888173.html

SOURCE OM1

Staff

Recent Posts

BioSig Technologies Confirms Full Compliance with Nasdaq Requirements for Continued Listing on The Nasdaq Capital Market

Los Angeles, CA, March 26, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BSGM) (“BioSig” or…

11 minutes ago

Dr. Lyudmila Sarder Receives Prestigious U.S. Congressional Award for Women’s History Month

"Trailblazing Physician and Advocate Receives U.S. Congressional Award for Advancing Healthcare Access and Community Service…

11 minutes ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

MIAMI, March 26, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™…

11 minutes ago

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada”,…

11 minutes ago

Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider

Oslo, Norway, 26 March, 2025 Reference is made to the stock exchange notice published by…

11 minutes ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Preclinical Data to Support Advancement Toward First-in-Human Clinical Trials SARASOTA, FL, March 26, 2025 (GLOBE…

11 minutes ago